Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial

医学 心力衰竭 心肌梗塞 冲程(发动机) 安慰剂 接种疫苗 不利影响 随机对照试验 流感疫苗 内科学 免疫学 替代医学 机械工程 工程类 病理
作者
Mark Loeb,Ambuj Roy,Hisham Dokainish,Antonio L. Dans,Lia M Palileo-Villanueva,Kamilu M Karaye,Jun Zhu,Yan Liang,Fastone Goma,Albertino Damasceno,Khalid F Alhabib,Gerald Yonga,Charles Mondo,Wael Almahameed,Arif Al Mulla,Vitheya Thanabalan,Purnima Rao‐Melacini,Alex Grinvalds,Tara McCready,Shrikant I. Bangdiwala,Salim Yusuf
出处
期刊:The Lancet Global Health [Elsevier BV]
卷期号:10 (12): e1835-e1844 被引量:9
标识
DOI:10.1016/s2214-109x(22)00432-6
摘要

Influenza increases the risk of cardiovascular events and deaths. We aimed to see whether influenza vaccination reduces death and vascular events in patients with heart failure.We did a pragmatic, randomised, double-blind, placebo-controlled trial in 30 centres (mostly hospitals affliated with universities or a research institute) in ten countries in Asia, the Middle East, and Africa (7 in India, 4 in Philippines, 4 in Nigeria, 6 in China, 1 in Zambia, 2 in Mozambique, 3 in Saudi Arabia, 1 in Kenya, 1 in Uganda, and 1 in Zambia). Participants (aged ≥18 years; 52·1% female; not disaggregated by race or ethnicity) with heart failure (New York Heart Association class II, III, or IV) were randomly assigned (1:1) by a centralised web-based system with block randomisation stratified by site, to receive 0·5 ml intramuscularly once a year for up to 3 years of either inactivated standard dose influenza vaccine or placebo (saline). We excluded people who had received influenza vaccine in 2 of the previous 3 years, and those likely to require valve repair or replacement. Those who administered assigned treatments were not masked and had no further role in the study. Investigators, study coordinators, outcome adjudicators, and participants were masked to group assignment. The first of two co-primary outcomes was a first-event composite for cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, and the second was a recurrent-events composite for cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalisation for heart failure. Outcomes were assessed every 6 months in the intention-to-treat population. Secondary outcomes were all-cause death, cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, all-cause hospitalisation, hospitalisation for heart failure, and pneumonia, both overall and during periods of peak influenza exposure. This study is registered with ClinicalTrials.gov, NCT02762851.Between June 2, 2015, and Nov 21, 2021, we enrolled 5129 participants and randomly assigned (1:1) 2560 (50·0%) to influenza vaccine and 2569 (50·0%) to placebo. The first co-primary outcome occurred in 380 (14·8%) of 2560 participants in the vaccine group and 410 (16·0%) of 2569 participants in the placebo group (hazard ratio [HR] 0·93 [95% CI 0·81-1·07]; p=0·30). The second co-primary outcome occurred in 754 (29·5%) of 2560 participants in the vaccine group and 819 (31·9%) of 2569 participants in the placebo group; HR 0·92 [95% CI 0·84-1·02]; p=0·12). The secondary outcomes of all-cause hospitalisations (HR 0·84 [95% CI 0·74-0·97]; p=0·013) and pneumonia (HR 0·58 [0·42-0·80]; p=0·0006) were significantly reduced in the vaccine group compared with in the placebo group but there was no significant difference between groups for all-cause death, cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalisation for heart failure. In a prespecified analysis, in which events were limited to periods of peak influenza circulation, the first co-primary outcome, and the secondary outcomes of all-cause death, cardiovasular death, and pneumonia were significantly lower in the vaccinated group than in the placebo group, whereas the second co-primary outcome and the secondary outcomes of non-fatal myocardial infarction, non-fatal stroke, all-cause hospitalisation, and hospitalisation for heart failure were not significantly lower.Although the prespecified co-primary outcomes during the entire period of observation were not statistically significant, the reduction during the peak influenza circulating period suggests that there is likely to be a clinical benefit of giving influenza vaccine, given the clear reduction in pneumonia, a moderate reduction in hospitalisations, and a reduction in cardiovascular events and deaths during periods of peak circulation of influenza. Taken in conjunction with previous trials and the observational studies, the collective data suggest benefit.UK Joint Global Health Trials Scheme and Canadian Institutes for Health Research Foundation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
戌博完成签到,获得积分10
2秒前
向广宇发布了新的文献求助10
2秒前
五号发布了新的文献求助10
2秒前
molihuakai的应助被哭泣的坚果强采纳,获得10
5秒前
别叫我Mars完成签到,获得积分10
5秒前
5秒前
善良的林完成签到,获得积分10
5秒前
金银铜铁铝完成签到,获得积分10
6秒前
aaabbb完成签到,获得积分10
6秒前
第一作者发布了新的文献求助10
7秒前
大气幻柏发布了新的文献求助10
8秒前
wang发布了新的文献求助10
8秒前
我不学化学完成签到,获得积分10
9秒前
9秒前
123完成签到 ,获得积分10
9秒前
优雅的ren完成签到,获得积分10
9秒前
hhy关闭了hhy的文献求助
10秒前
10秒前
我在人间凑数的日子完成签到,获得积分10
11秒前
香蕉觅云的应助被lmy采纳,获得10
11秒前
皮卡丘发布了新的文献求助30
11秒前
11秒前
14秒前
15秒前
15秒前
16秒前
郑小乔发布了新的文献求助10
16秒前
道生发布了新的文献求助10
16秒前
17秒前
17秒前
金银铜铁铝关注了科研通微信公众号
17秒前
所所的应助被贝贝南瓜采纳,获得10
17秒前
LPW完成签到,获得积分10
17秒前
zhxwzy完成签到,获得积分10
17秒前
板蓝根完成签到,获得积分10
17秒前
ly完成签到 ,获得积分10
18秒前
瘦肉包子完成签到,获得积分10
19秒前
英俊的铭的应助被图图采纳,获得10
19秒前
1263428155完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188210
求助须知:如何正确求助?哪些是违规求助? 9576001
关于积分的说明 21844898
捐赠科研通 7786081
什么是DOI,文献DOI怎么找? 3435220
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482139